The ORL1 receptor: Molecular pharmacology and signalling mechanisms

NeuroSignals

Volumn 11, Issue 4, 2002, Pages 197-212

  New, David C ^a   Wong, Yung H ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

G proteins; Nociceptin; ORL1; Pharmacology, ORL1 receptor; Receptor structure; Signalling pathways

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; LIGAND; NOCICEPTIN; OPIATE RECEPTOR; RECEPTOR SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN; ION CHANNEL; NOCICEPTIN RECEPTOR; OPIATE PEPTIDE;

BINDING AFFINITY; HUMAN; MEDICAL RESEARCH; PHYSIOLOGY; RECEPTOR INTRINSIC ACTIVITY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; PAIN; PATHOPHYSIOLOGY;

ANIMALS; GTP-BINDING PROTEINS; HUMANS; ION CHANNELS; MAP KINASE SIGNALING SYSTEM; OPIOID PEPTIDES; PAIN; RECEPTORS, OPIOID; SIGNAL TRANSDUCTION;

EID: 0036632334     PISSN: 1424862X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065432     Document Type: Review

References (143)

1. Bunzow JR, Saez C, Mortrud M, Bouvier C, Williams JT, Low M, Grandy DK: Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a μ-, δ- or κ-opioid receptor type. FEBS Lett 1994;347:284-288.
2. Chen Y, Fan Y, Liu J, Mestek A, Tian M, Kozak CA, Yu L: Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family. FEBS Lett 1994;347:279-283.
3. Fukuda K, Kato S, Mori K, Nishi M, Takeshima H, Iwabe N, Miyata T, Houtani T, Sugimoto T: cDNA cloning and regional distribution of a novel member of the opioid receptor family. FEBS Lett 1994;343:42-46.
4. 1, a novel member of the opioid receptor family: Cloning, functional expression and localization. FEBS Lett 1994;341:33-38.
5. Wang JB, Johnson PS, Imai Y, Persico AM, Ozenberger BA, Eppler CM, Uhl GR: cDNA cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Lett 1994;348:75-79.
6. Wick MJ, Minnerath SR, Lin X, Elde R, Law PY, Loh HH: Isolation of a novel cDNA encoding a putative membrane receptor with high homology to the cloned μ-, δ-, and κ-opioid receptors. Brain Res Mol Brain Res 1994;27:37-44.
7. Halford WP, Gebhardt BM, Carr DJ: Functional role and sequence analysis of a lymphocyte orphan opioid receptor. J Neuroimmunol 1995;59:91-101.
8. Lachowicz JE, Shen Y, Monsma FJ Jr, Sibley DR: Molecular cloning of a novel G protein-coupled receptor related to the opiate receptor family. J Neurochem 1995;64:34-40.
9. Pan YX, Cheng J, Xu J, Rossi G, Jacobson E, Ryan-Moro J, Brooks AI, Dean GE, Standifer KM, Pasternak GW: Cloning and functional characterization through functional mapping of a κ3-related opioid receptor. Mol Pharmacol 1995;47:1180-1188.
10. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M: International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996;48:567-592.
11. Hamon M: The new approach to opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 1998;358(suppl 2):5A53.
12. 1 receptor. Nature 1995;377:532-535.
13. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ, Civelli O: Orphanin FQ: A neuropeptide that activates an opioid-like G protein-coupled receptor. Science 1995;270:792-794.
14. Mogil JS, Pasternak GW: The molecular and behavioural pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev 2001;53:381-415.
15. 1) receptor. Peptides 2000;21:907-917.
16. Reinscheid RK, Nothacker H, Civelli O: The orphanin FQ/nociceptin gene: Structure, tissue distribution of expression and functional implications obtained from knockout mice. Peptides 2000;21:901-906.
17. Chavkin C, Goldstein A: Specific receptor for the opioid dynorphin: Structure-activity relationships. Proc Natl Acad Sci USA 1981;78:6543-6547.
18. Hruby VJ, Gehrig CA: Recent developments in the design of receptor specific opioid peptides. Med Res Rev 1989;9:343-401.
19. Reinscheid RK, Ardati A, Monsma FJ Jr, Civelli O: Structure-activity relationship studies on the novel neuropeptide orphanin FQ. J Biol Chem 1996;271:14163-14168.
20. Reinscheid RK, Higelin J, Henningsen RA, Monsma FJ Jr, Civelli O: Structures that delineate orphanin FQ and dynorphin A pharmacological selectivities. J Biol Chem 1998;273:1490-1495.
21. Meng F, Taylor LP, Hoversten MT, Ueda Y, Ardati A, Reinscheid RK, Monsma FJ, Watson SJ, Civelli O, Akil H: Moving from the orphanin FQ receptor to an opioid receptor using four point mutations. J Biol Chem 1996;271:32016-32020.
22. Mollereau C, Moulédous L, Lapalu S, Cambois G, Moisand C, Butour JL, Meunier JC: Distinct mechanisms of activation of the opioid receptor-like 1 and κ-opioid receptors by nociceptin and dynorphin A. Mol Pharmacol 1999;55:324-331.
23. 1 receptor transmembrane-binding domain. Mol Pharmacol 2000;57:495-502.
24. 1 receptor and its complex with nociceptin. Protein Eng 1998;11:1163-1179.
25. Joseph MP, Maigret B, Bonnafus JC, Marie J, Scherega HA: A computer modeling postulated mechanism for angiotensin II receptor activation. J Protein Chem 1997;14:381-398.
26. 1A angiotensin II receptor induces its constitutive activation. J Biol Chem 1997;272:1822-1826.
27. 2 receptor induced by mutations in transmembrane helices III and VI. Mol Pharmacol 1999;55:92-101.
28. Dooley CT, Houghten RA: Orphanin FQ: Receptor binding and analog structure-activity relationships in rat brain. Life Sci 1996;59:PL23-PL29.
29. 14]nociceptin. J Biol Chem 2000;275:29268-29274.
30. Pan YX, Xu J, Ryan-Moro J, Mathis JP, Hom JSH, Mei JF, Pasternak GW: Dissociation of affinity and efficacy in KOR-3 chimeras. FEBS Lett 1996;395:207-210.
31. Mathis JP, Ryan-Moro J, Chang A, Hom JSH, Scheinberg DA, Pasternak GW: Biochemical evidence for orphanin FQ/nociceptin receptor heterogeniety in mouse brain. Biochem Biophys Res Commun 1997;230:462-465.
32. Dooley CT, Houghten RA: Orphanin FQ/nociceptin receptor binding studies. Peptides 2000;21:949-960.
33. Adapa ID, Toll L: Relationship between binding affinity and functional activity of nociceptin/orphanin FQ. Neuropeptides 1997;31:403-408.
34. 14-orphanin FQ with the orphanin FQ receptor: Kinetics and modulation by cations and guanine nucleotides. Mol Pharmacol 1997;51:816-824.
35. 1 receptor by nociceptin, nociceptin analogs and opioids. Eur J Pharmacol 1997;321:97-103.
36. Quigley DI, Arttamangkul S, Allen RG, Grandy DK: Integrity of orphanin FQ/nociceptin: Implications for establishing a reliable binding assay. Peptides 2000;21:1111-1118.
37. Yu J, Chait BT, Toll L, Kreek MJ: Nociceptin in vitro biotransformation in human blood. Peptides 1996;17:873-876.
38. Sandin J, Georgieva J, Silberring J, Terenius L: In vivo metabolism of nociceptin/orphanin FQ in rat hippocampus. Neuroreport 1999;10:71-76.
39. Suder P, Kotlinska J, Smoluch MT, Sallberg M, Silberring J: Metabolic fate of nociceptin/orphanin FQ in the rat spinal cord and biological activity of its released fragment. Peptides 1999;20:239-247.
40. Guerrini R, Calo G, Rizzi A, Bianchi C, Lazarus LH, Salvadori S, Temussi PA, Regoli D: Address and message sequences for the nociceptin receptor: A structure-activity study of nociceptin-(1-13)-peptide amide. J Med Chem 1997;40:1789-1793.
41. Varani K, Calo G, Rizzi A, Merighi S, Toth G, Guerrini R, Salvadori S, Borea PA, Regoli D: Nociceptin receptor binding in mouse forebrain membranes: Thermodynamic characteristics and structure-activity relationships. Br J Pharmacol 1998;125:1485-1490.
42. 2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors. Br J Pharmacol 1999;127:123-130.
43. Calo G, Guerrini R, Rizzi A, Salvadori S, Regoli D: Pharmacology of nociceptin and its receptor: A novel therapeutic target. Br J Pharmacol 2000;129:1261-1283.
44. Okada K, Sujaku T, Chuman Y, Nakashima R, Nose T, Costa T, Yamada Y, Yokoyama M, Nagahisa A, Shimohigashi Y: Highly potent nociceptin analog containing the Arg-Lys triple repeat. Biochem Biophys Res Commun 2000;278:493-498.
45. 15]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: In vitro and in vivo studies. J Pharmacol Exp Ther 2002;300:57-63.
46. 2: Identification of highly potent agonists of the nociceptin/orphanin FQ receptor. J Med Chem 2001;44:3956-3964.
47. 2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J Med Chem 1998;41:3360-3366.
48. 1 receptor endogenously expressed in mouse N1E-115 neuroblastoma cells. Neuroreport 1999;10:1127-1131.
49. 1). Peptides 2000;21:1147-1154.
50. Calo G, Rizzi A, Marzola G, Guerrini R, Salvadori S, Beani L, Regoli D, Bianchi C: Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. Br J Pharmacol 1998;125:373-378.
51. Guerrini R, Calo G, Bigoni R, Rizzi A, Varani K, Toth G, Gessi S, Hashiba E, Hashimoto Y, Lambert DG, Borea PA, Tomatis R, Salvadori S, Regoli D: Further studies on nociceptin-related peptides: Discovery of a new chemical template with antagonist activity on the nociceptin receptor. J Med Chem 2000;43:2805-2813.
52. 2, a new selective nociceptin receptor antagonist. Br J Pharmacol 2000;129:1183-1193.
53. 2 selectively antagonizes nociceptin/orphanin FQ-stimulated G-protein activation in rat brain. J Pharmacol Exp Ther 2000;294:428-433.
54. 2, prevents the effects of nociceptin in neuropathic rats. Brain Res 2001;905:127-133.
55. 2 on anti-nociception induced by intrathecal administration of nociceptin in rats. Regul Pept 2001;101:81-85.
56. 2 antagonizes nociceptin-induced hypotension, bradycardia, and hindquarters vasodilation in the anesthetized rat. Can J Physiol Pharmacol 2002;80:31-35.
57. 2 in mice. Neurosci Lett 2001;316:25-28.
58. 1 receptors identified from a conformationally constrained peptide combinatorial library. J Biol Chem 1999;274:27513-27522.
59. Calo G, Bigoni R, Rizzi A, Guerrini R, Salvadori S, Regoli D: Nociceptin/orphanin FQ receptor ligands. Peptides 2000;21:935-947.
60. Wichmann J, Adam G, Rover S, Cesura AM, Dautzenberg FM, Jenck F: 8-Acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists. Bioorg Med Chem Lett 1999;9:2343-2348.
61. 1 (orphanin FQ/nociceptin) receptor. J Med Chem 2000;43:1329-1338.
62. Rover S, Wichmann J, Jenck F, Adam G, Cesura AM: ORL1 receptor ligands: Structure-activity relationships of 8-cycloalkyl-1-phenyl-1,3,8-triaza-spiro[4. 5]decan-4-ones. Bioorg Med Chem Lett 2000;10:831-834.
63. 1: Anxiolytic profile in the rat. Proc Natl Acad Sci USA 2000;97:4938-4943.
64. Wichmann J, Adam G, Rover S, Hennig M, Scalone M, Cesura AM, Dautzenberg FM, Jenck F: Synthesis of (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)- 1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties. Eur J Med Chem 2000;35:839-851.
65. 1 receptor in vitro and lack of tolerance in vivo. J Pharmacol Exp Ther 2001;298:812-819.
66. 1 receptor agonist, Ro64-6198, on rodent neurological function. Neuropharmacology 2001;41:97-107.
67. Rizzi D, Bigoni R, Rizzi A, Jenck F, Wichmann J, Guerrini R, Regoli D, Calo G: Effects of Ro 64-6198 in nociceptin/orphanin FQ-sensitive isolated tissues. Naunyn Schmiedebergs Arch Pharmacol 2001;363:551-555.
68. 1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxy-methyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397). J Med Chem 1999;42:5061-5063.
69. 1 receptor antagonist. Eur J Pharmacol 2000;402:45-53.
70. 1 receptor-mediated inhibition of noradrenaline release in human and rat neocortical slices. Br J Pharmacol 2002;135:800-806.
71. Olianas MC, Onali P: Pharmacological properties of nociceptin/orphanin FQ-induced stimulation and inhibition of cyclic AMP formation in distinct layers of rat olfactory bulb. Br J Pharmacol 2002;135:233-238.
72. Vaughan CW, Connor M, Jennings EA, Marinelli S, Allen RG, Christie MJ: Actions of nociceptin/orphanin FQ and other prepronociceptin products on rat rostral ventromedial medulla neurons in vitro. J Physiol (Lond) 2001;534:849-859.
73. Grond S, Gabriel A, Pietruck C, Yu LC, Xie GX, Pierce Palmer P: Bi-directional modulation of 5-hydroxytryptamine-induced plasma extravasation in the rat knee joint by nociceptin. Neuroscience 2001;103:1085-1092.
74. 1) receptor antagonist, JTC-801. Br J Pharmacol 2002;135:323-332.
75. 1 and μ-opioid receptor antisera label different fibers in areas involved in pain processing. J Comp Neurol 1998;399:373-383.
76. Pan Z, Hirakawa N, Fields HL: A cellular mechanism for the bidirectional pain-modulating actions of orphanin FQ/nociceptin. Neuron 2000;26:515-522.
77. Xu X, Grass S, Hao J, Xu IS, Wiesenfeld-Hallin Z: Nociceptin/orphanin FQ in spinal nociceptive mechanisms under normal and pathological conditions. Peptides 2000;21:1031-1036.
78. Ito S, Okuda-Ashitaka E, Minami T: Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res 2001;41:299-332.
79. 1 in neuroblastoma x glioma NG108-15 hybrid cells. FEBS Lett 1997;403:91-94.
80. 16 proteins. J Neurochem 1998;71:2203-2210.
81. Cheng ZJ, Fan GH, Zhao J, Zhang Z, Wu YL, Jiang LZ, Zhu Y, Pei G, Ma L: Endogenous opioid receptor-like receptor in human neuroblastoma SK-N-SH cells: Activation of inhibitory G protein and homologous desensitization. Neuroreport 1997;8:1913-1918.
82. i signaling. Oncogene 2001;20:1615-1625.
83. 1 receptor induces supersensitization of adenylyl cyclase. Neuroreport 1999;10:2901-2905.
84. 2+ pathway. Biochem Biophys Res Commun 1997;240:304-308.
85. Chan JS, Chiu TT, Wong YH: Activation of type II adenylyl cyclase by the cloned μ-opioid receptor: Coupling to multiple G proteins. J Neurochem 1995;65:2682-2689.
86. Tsu RC, Chan JS, Wong YH: Regulation of multiple effectors by the cloned δ-opioid receptor: Stimulation of phospholipase C and type II adenylyl cyclase. J Neurochem 1995;64:2700-2707.
87. Armstead W: NOC/oFQ activates PKC and generates superoxide to impair hypotensive cerebrovasodilation after hypoxia/ischemia. Med Sci Monit 2002;8:BR8-BR14.
88. 16 couple a wide variety of receptors to phospholipase C. J Biol Chem 1995;270:15175-15180.
89. s-coupled receptors to the stimulation of phospholipase C. Br J Pharmacol 2001;132:1431-1440.
90. 16, a G protein α subunit specifically expressed in hematopoietic cells. Proc Natl Acad Sci USA 1991;88:5587-5591.
91. q class: Expression in murine tissues and in stromal and hematopoietic cell lines. Proc Natl Acad Sci USA 1991;88:10049-10053.
92. Wick MJ, Minnerath SR, Roy S, Ramakrishnan S, Loh HH: Expression of alternate forms of brain opioid 'orphan' receptor mRNA in activated human peripheral blood lymphocytes and lymphocytic cell lines. Brain Res Mol Brain Res 1995;32:342-347.
93. Peluso J, LaForge KS, Matthes HW, Kreek MJ, Kieffer BL, Gaveriaux-Ruff C: Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells. J Neuroimmunol 1998;81:184-192.
94. Price MA, Cruzalegui FH, Treisman R: The p38 and ERK MAP kinase pathways cooperate to activate ternary complex factors and c-fos transcription in response to UV. EMBO J 1996;15:6552-6563.
95. Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, DePinho RA, Panayotatos N, Cobb MH, Yancopoulos GD: ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991;65:663-675.
96. Han J, Lee JD, Bibbs L, Ulevitch RJ: A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994;265:808-811.
97. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Avruch J, Woodgett JR: The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994;369:156-160.
98. 1 receptor in Chinese hamster ovary cells. Neuroreport 1998;9:2703-2708.
99. Fukuda K, Shoda T, Morikawa H, Kato S, Mori K: Activation of mitogen-activated protein kinase by the nociceptin receptor expressed in Chinese hamster ovary cells. FEBS Lett 1997;412:290-294.
100. Lou LG, Zhang Z, Ma L, Pei G: Nociceptin/orphanin FQ activates mitogen-activated protein kinase in Chinese hamster ovary cells expressing opioid receptor-like receptor. J Neurochem 1998;70:1316-1322.
101. i-coupled signaling pathway: Evidence for distinct mechanisms of agonist-mediated desensitization. J Neurochem 1998;71:1024-1033.
102. 1 receptors couple to phosphorylation and activation of p38 MAPK in NG108-15 cells and this is regulated by protein kinase A and protein kinase C. J Neurochem 1999;73:1502-1509.
103. 1 receptor through multiple G proteins. J Pharmacol Exp Ther 2000;295:1094-1100.
104. Law PY, Wong YH, Loh HH: Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 2000;40:389-430.
105. Igaz P, Toth S, Falus A: Biological significance of the JAK-STAT pathway: Lessons from knockout mice. Inflamm Res 2001;50:435-441.
106. Saito Y, Maruyama K, Saido TC, Kawashima S: Overexpression of a neuropeptide nociceptin/orphanin FQ precursor gene, N23K/N27K, induces neurite outgrowth in mouse NS20Y cells. J Neurosci Res 1997;48:397-406.
107. i2 proteins of v-fms-induced proliferation and transformation via Src-kinase and STAT3. Oncogene 1999;18:6335-6342.
108. o protein. Science 2000;287:142-144.
109. Ram PT, Iyengar R: G protein coupled receptor signaling through the Src and Stat3 pathway: Role in proliferation and transformation. Oncogene 2001;20:1601-1606.
110. Lowes VL, Ip NY, Wong YH: Integration of signals from receptor tyrosine kinases and G protein-coupled receptors. Neurosignals 2002;11:5-19.
111. 2+ in the SH-SY5Y human neuroblastoma cell line. Br J Pharmacol 1996;118:205-207.
112. 2+ channel inhibition and its desensitization in NG108-15 cells. Eur J Pharmacol 1998;351:247-252.
113. 2+ channel current in rat sensory neurons by a G-protein-independent mechanism. J Neurosci 1997;17:8721-8728.
114. Borgland SL, Connor M, Christie MJ: Nociceptin inhibits calcium channel currents in a subpopulation of small nociceptive trigeminal ganglion neurons in mouse. J Physiol (Lond) 2001;536:35-47.
115. Huguenard JR: Low-threshold calcium currents in central nervous system neurons. Annu Rev Physiol 1996;58:329-348.
116. Abdulla FA, Smith PA: Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons. J Neurosci 1998;18:9685-9694.
117. Ossipov MH, Lopez Y, Nichols ML, Bian D, Porreca F: Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury. Neurosci Lett 1995;199:83-86.
118. 1) receptor agonist, on the thermal hyperalgesia induced by unilateral constriction injury to the sciatic nerve in the rat. Neurosci Lett 1997;224:107-110.
119. Hao JX, Xu IS, Wiesenfeld-Hallin Z, Xu XJ: Anti-hyperalgesic and anti-allodynic effects of intrathecal nociceptin/orphanin FQ in rats after spinal cord injury, peripheral nerve injury and inflammation. Pain 1998;76:385-393.
120. 2+ channel currents of acutely dissociated rat periaqueductal grey neurons. J Physiol (Lond) 1998;509:47-58.
121. 1 receptor ligand nociceptin on membrane properties of rat periaqueductal gray neurons in vitro. J Neurosci 1997;17:996-1003.
122. 1ψ-nociceptin(1-13), nocistatin and prepronociceptin(154-181) effects on calcium channel currents and a potassium current in rat locus coeruleus in vitro. Br J Pharmacol 1999;128:1779-1787.
123. 2+ channels in rat sympathetic ganglion neurons. Neurosci Lett 2000;296:121-124.
124. Knoflach F, Reinscheid RK, Civelli O, Kemp JA: Modulation of voltage-gated calcium channels by orphanin FQ in freshly dissociated hippocampal neurons. J Neurosci 1996;16:6657-6664.
125. Yu TP, Fein J, Phan T, Evans CJ, Xie CW: Orphanin FQ inhibits synaptic transmission and long-term potentiation in rat hippocampus. Hippocampus 1997;7:88-94.
126. Manabe T, Noda Y, Mamiya T, Katagiri H, Houtani T, Nishi M, Noda T, Takahashi T, Sugimoto T, Nabeshima T, Takeshima H: Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors. Nature 1998;394:577-581.
127. Matthes H, Seward EP, Kieffer B, North RA: Functional selectivity of orphanin FQ for its receptor coexpressed with potassium channel subunits in Xenopus laevis oocytes. Mol Pharmacol 1996;50:447-450.
128. + (GIRK) channel. Brain Res Mol Brain Res 1997;45:117-126.
129. Connor M, Vaughan CW, Chieng B, Christie MJ: Nociceptin receptor coupling to a potassium conductance in rat locus coeruleus neurones in vitro. Br J Pharmacol 1996;119:1614-1618.
130. + conductance in dorsal raphe nucleus neurones. Br J Pharmacol 1996;117:1609-1611.
131. + current induced by nociceptin in medullary dorsal horn neurons. Neuroreport 2001;12:645-648.
132. Amano T, Matsubayashi H, Tamura Y, Takahashi T: Orphanin FQ-induced outward current in rat hippocampus. Brain Res 2000;853:269-274.
133. 1 and opiate receptor mechanisms. J Neurophysiol 1999;82:1776-1785.
134. Tallent MK, Madamba SG, Siggins GR: Nociceptin reduces epileptiform events in CA3 hippocampus via presynaptic and postsynaptic mechanisms. J Neurosci 2001;21:6940-6948.
135. + channel-dependent mechanisms in piglet hypoxic/ischemic impaired nociceptin/orphanin FQ-induced cerebrovasodilation. Brain Res 2000;884:51-58.
136. Pei G, Ling K, Pu L, Cunningham MD, Ma L: Nociceptin/orphanin FQ stimulates extracellular acidification and desensitization of the response involves protein kinase C. FEBS Lett 1997;412:253-256.
137. Zhao J, Zhang Y, Xin SM, Ma L, Pei G: Attenuation of nociceptin/orphanin FQ-induced signaling by N-methyl-D-aspartate in neuronal cells. Neuroreport 1998;9:631-636.
138. Pu L, Bao GB, Ma L, Pei G: Acute desensitization of nociceptin/orphanin FQ inhibition of voltage-gated calcium channels in freshly dissociated hippocampal neurons. Eur J Neurosci 1999;11:3610-3616.
139. 1 receptor in human neuroblastoma cells. Neuroreport 2001;12:3159-3163.
140. Devi LA: Heterodimerization of G-protein-coupled receptors: Pharmacology, signaling and trafficking. Trends Pharmacol Sci 2001;22:532-537.
141. 16. Neurosignals 2002;11:115-122.
142. George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, O'Dowd BF: Oligomerization of μ- and δ-opioid receptors. J Biol Chem 2000;275:26128-26135.
143. i-coupled receptors. Mol Pharmacol 2000;57:13-23.